Toronto, Ontario, Canada / TheNewswire / December 8, 2016: Open Source Health Inc. (CSE:OSH), (Frankfurt:0OS), a cloud based precision medicine platform for women called myAVA that puts control into the hands of women to educate, advocate and collaborate on their own healthcare is pleased to provide an update on the roll out of the platform with the first group of women in Atlanta.

 “Every woman’s genomic report has provided life-altering information and has had an impact in her day-to-day life,” states Sonya Satveit, CEO of Open Source Health Inc., “Our patients are feeling empowered by their newfound knowledge and report that their healthcare providers are taking their concerns seriously and integrating this information into treatment and screening plans.”

The Precision PCOS program launched in June 2016 at the Medici Medical Arts Clinic in Atlanta with a cohort of women who were selected to enter the program to form the Patient Advisory Board. This group of women has been instrumental in influencing patient centered design around envisioning what the next generation of healthcare delivery will look like.

The launch of the myAVA platform included an initial assessment and review, specimen collection and diagnosis via the mini-myAVA testing panel. This revealed a number of unaddressed hormonal, metabolic and nutritional deficiencies in each woman.  At the follow- up consultation a personalized care program was put in place by the care team, which included: lifestyle changes, medication, nutritional supplements, as well as further testing and follow-up.  The highlight of the care program is the introduction of myAVA’s Precision Nutrition Program, with a focus on addressing the insulin resistance.  Insulin resistance is both prevalent and under diagnosed in women with PCOS, myAva’s Precision Nutrition Program utilizes the Food Insulin Demand, a combined index count based on metabolic results. Once incorporated, the women have reported significant positive effects such as unprecedented weight loss and symptom relief, and an incredible 100% indicated an improvement in overall well being.  

The next stage involved the analysis and interpretation of each woman’s DNA sequencing, specifically their exome variance, to determine disease risk and develop screening programs to monitor anyone with high risk results.  This included variances and risk assessment for cancer, heart disease, autoimmune issues, mental health, reproductive health and drug metabolism.

The women are about to enter the next major phase of the program whereby they will be presented with their full molecular - digital version of Her.  The integration of the proteomic, metabolomic and micro-biome data will indicate the overall health of each woman and identify potential diseases states and progression.  This base line digital version of Her will then be established and monitored every 90 days, tracking the outcomes of her integrative treatments and her trending towards overall wellness.

 

About Open Source Health Inc.:

OSH has developed a cloud-based precision medicine platform called myAVA, which is offered on a monthly subscription basis to clinics and providers to enable the delivery of precision medicine, specifically for women’s health.  By collecting and analyzing molecular-level data we will create a digital version of each patient, uncovering disease markers at an early stage allowing women and their providers to take a proactive approach to achieve optimal health. myAVA sets a new standard of care for women's health.  The initial launch of myAVA is focused at PCOS (Polycystic Ovary Syndrome), which affects 7 million women in the United States and 116 million women worldwide.

For more information, visit www.opensourcehealth.com

Contact:

For further information, please contact Investor Relations at Open Source Health Inc.
Toll Free: 1.866.403.1933 in North America

International Calling: +01.647.872.9986       
http://www.opensourcehealth.com/contact-new/

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Open Source Health Inc. (“OSH”), including, but not limited to, the impact of general economic conditions, industry conditions and the uncertainty of obtaining additional financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

The forward-looking statements contained in this press release are made as of the date of this press release, and OSH does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.